FindMyKOL

Joshua Baker, MD

Basic profile

Rheumatology

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionPhiladelphia, PA · NortheastSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLFindMyKOL type: NationalLatest publicationNot yet indexedOnline presenceNot yet checkedPayments2021 onwardNIH funding2013–2025Why? →

Joshua Baker is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials ↓
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
5NIH grants · 2013–2025

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Amgen
    Program year20242 paymentsResearch
    $68,467
  • Pfizer
    Program year20243 paymentsResearch
    $4,470
  • Pfizer
    Program year20231 paymentResearch
    $3,200
All 5 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    28.1%
    Folate Analog Metabolic Inhibitor23.8%
    Methotrexate100%
    Part D≥12 patients
    TNF inhibitor4.3%
    Humira100%
    Part D<11 patients
  • Musculoskeletal

    20.6%
    Alkaloid7.8%
    Colchicine100%
    Part D<11 patients
    Nonsteroidal Anti-inflammatory Drug7.1%
    Diclofenac Sodium100%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    18.5%
    Corticosteroid13.2%
    Prednisone100%
    Part D≥12 patients
    Aminosalicylate5.3%
    Sulfasalazine100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

5 NIH research awards on record, funded 2013–2025 per NIH RePORTER. The latest:

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”